Company: CRNX
Filing Date: 2025-06-26
Form Type: 8-K
Source: 0000950170-25-090405
Chunk: 2

Company: Crinetics Pharmaceuticals, Inc.
Filing Date: 2025-06-26
Form: 8-K
Item: Item 8.01
Chunk 2
---
 expansion dose for the Phase 2 dose expansion phase and confirm the tumor sub-types that will be enrolled in the expansion cohorts. The Company expects to enroll up to 150 participants across both Phase 1 and Phase 2 of the trial.

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. All statements other than statements of historical facts contained in this Current Report on Form 8-K are forward-looking statements, including statements regarding the Company’s pipeline development and clinical trial programs, clinical development strategy, and trial design and expected enrollment for the Company’s Phase 1/2 study BRAVESST2 of CRN09682. These forward-looking statements speak only as of the date of this Current Report on Form 8-K and are subject to a number of known and unknown risks, uncertainties, assumptions, and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, without limitation, the risks and uncertainties described in the Company’s periodic filings with the SEC. The events and circumstances reflected in the Company’s forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Additional information on risks facing the Company can be found under the heading “ Risk Factors” in the Company’s periodic filings with the SEC, including its annual report on Form 10-K for the year

ended December 31, 2024 and quarterly report on Form 10-Q for the quarter ended March 31, 2025. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by applicable law, the Company does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

  Exhibit No.      Description                                                                  
 ────────────────────────────────────────────────────────────────────────────────────────────────
         99.1      Slide Presentation.                                                          
          104      Cover Page Interactive Data File (embedded within the Inline XBRL document)  

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed